In this issue:
First-line nivolumab + ipilimumab in unresectable malignant pleural mesothelioma
Impact of BMI on first-line pembrolizumab in NSCLC with PD-L1 expression ≥50%
First-line avelumab in advanced NSCLC
First-line platinum-etoposide ±durvalumab ±tremelimumab for extensive-stage SCLC
Biomarker-driven therapies for previously treated squamous NSCLC
Chronic effects of PM2.5 exposure on lung cancer
Irinotecan + cisplatin vs. etoposide + cisplatin for resected high-grade neuroendocrine lung carcinoma
First-line afatinib ±cetuximab for EGFR-mutated NSCLC
High-intensity statins improve clinical activity of PD-1 inhibitors
Local thoracic surgery outcomes for stage IV NSCLC
PD-L1 polymorphisms for predicting survival in anti-PD-1-treated advanced NSCLC
Please login below to download this issue (PDF)